sameAs
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.Carboplatin: an active drug in metastatic breast cancer.Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.Differential colorectal carcinogenesis: Molecular basis and clinical relevanceRole of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.Venous International Assessment, VIA scale, validated classification procedure for the peripheral venous system.Oxaliplatin: results in colorectal carcinoma.Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.BRCA1 Alternative splicing landscape in breast tissue samples.First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD studyNew chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer.APC Yin-Yang haplotype associated with colorectal cancer risk.Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.Clinical practice guidelines on antiemetics in oncology.Chemotherapy for gastric cancer.New target-based agents involve new clinical trial designs.Guidelines for the detection and treatment of liver metastases of colorectal cancer.Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families.Frequency and variability of genomic rearrangements on MSH2 in Spanish Lynch Syndrome families.Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.Consensus on the treatment of pancreatic cancer in Spain.Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
P50
Q30313248-ED0DE23E-A213-4CF9-A7A4-2CA5762863E3Q30316008-18BF4DE6-AF89-44B0-81D3-CE83AA7F67E4Q30779447-328B27CD-FF51-4BCB-88A3-ED8761388ED6Q31136880-7405F04D-E849-4A41-BE84-9372D4DF5EB8Q33334087-F3CB24D2-83B7-430B-806E-895EFA0A0D99Q33342773-7E717297-47D4-45F2-A343-E5D7E3E94CE6Q33364043-3A991D28-5B96-42B3-9BBD-21D4FDED54ABQ33374769-66A87A18-EBCE-46BE-A4B3-475E24FBC7B6Q33382045-070DE5CB-684E-4C98-BFF6-6788F762E845Q33493000-6894C895-341B-4B36-B612-2B50A775060EQ33495682-18AB0A4D-9573-4A65-9097-F0E2F44F79F4Q33500658-22EE4C84-1815-4D80-B7DB-9F846B57495DQ34308855-601CD667-FB38-417E-AC23-1D2E06DF3710Q34372111-3B62A700-53DB-4D73-8EF6-231928F54341Q34391153-6D5F6C39-A038-4207-8018-82598E2D04E0Q34486371-D89CA756-69F3-4662-9554-60C29C5E3910Q34534314-52D48A58-1F62-460D-9E1D-F37AE94C0AE9Q34590731-FEC9D837-C220-4A34-86CC-871D160A957EQ34630237-95BA7979-CE58-4911-BE26-AED80745C018Q34656123-8C703482-B470-4393-9F28-A2D52333BA4EQ34979779-B6AA6E8E-0B60-400D-AA9D-7B949B88FE69Q35156137-008D1D17-EFC1-44B0-861F-BFC9C9CA7DC2Q35368266-B77BE4E7-6B0C-4CDF-B97B-A8D30C78E936Q35705210-43DC78C3-9937-4389-8472-C874E58CA01CQ35787977-1440AA0E-4328-40E4-9109-68883F9A9C8EQ36102824-9C02C38B-7CC7-4C58-974C-2AA5A4B9D284Q36125075-19DDB081-8D6F-490D-BAA4-8FBCD9C3682EQ36244070-0DEFF027-1A28-4532-BADC-CE44479C9B5EQ36318892-62117A9E-6E13-4A79-A426-9B7E50BA3FB0Q36319019-6FEA5471-3BDB-4B37-913E-681CA3C194E8Q36334870-6B485740-1C9E-4C05-B59E-41A3859C5DBFQ36398226-8050B4E4-59FE-4718-A26E-2A55BA1561D0Q36585602-F8BD6877-77E6-405F-AE0A-CBCBC7543352Q37022666-160B7EFE-CFF0-473D-B2D6-8D73F66A84DFQ37043816-C80E78E3-E5A7-4ADC-92F6-B14DDDC80521Q37164520-48173943-AEDB-4885-9F1F-FF005DC3E9F6Q37270934-148C0C14-4E33-419B-9891-DCFF7AC504F7Q37477973-6B477ABF-EC89-4748-B92E-CCEFDF02F927Q37487167-535CE4ED-52DC-4EB7-89E1-C3D4F0D48E1FQ37539436-5C633AA7-F351-472C-9D89-CE7A58DF1E03
P50
subject
description
Hispaania arst
@et
Médico Español
@es
Spaans arts
@nl
Spanish physician
@en
Spanish physician
@en-ca
Spanish physician
@en-gb
dochtúir Spáinneach
@ga
medic spaniol
@ro
medico spagnolo
@it
metge espanyol
@ca
name
Eduardo Díaz-Rubio García
@ca
Eduardo Díaz-Rubio García
@sq
Eduardo Díaz-Rubio
@ast
Eduardo Díaz-Rubio
@br
Eduardo Díaz-Rubio
@co
Eduardo Díaz-Rubio
@da
Eduardo Díaz-Rubio
@de
Eduardo Díaz-Rubio
@en
Eduardo Díaz-Rubio
@es
Eduardo Díaz-Rubio
@fr
type
label
Eduardo Díaz-Rubio García
@ca
Eduardo Díaz-Rubio García
@sq
Eduardo Díaz-Rubio
@ast
Eduardo Díaz-Rubio
@br
Eduardo Díaz-Rubio
@co
Eduardo Díaz-Rubio
@da
Eduardo Díaz-Rubio
@de
Eduardo Díaz-Rubio
@en
Eduardo Díaz-Rubio
@es
Eduardo Díaz-Rubio
@fr
altLabel
Eduardo Díaz-Rubio García
@ast
Eduardo Díaz-Rubio García
@en
Eduardo Díaz-Rubio García
@es
Eduardo Díaz-Rubio García
@fr
Eduardo Díaz-Rubio García
@nl
diaz-rubio e
@en
diaz-rubio garcia e
@en
diazrubio e
@en
prefLabel
Eduardo Díaz-Rubio García
@ca
Eduardo Díaz-Rubio García
@sq
Eduardo Díaz-Rubio
@ast
Eduardo Díaz-Rubio
@br
Eduardo Díaz-Rubio
@co
Eduardo Díaz-Rubio
@da
Eduardo Díaz-Rubio
@de
Eduardo Díaz-Rubio
@en
Eduardo Díaz-Rubio
@es
Eduardo Díaz-Rubio
@fr
P1006
P214
P950
P1006
P106
P1580
P2031
1970-01-01T00:00:00Z
P21
P213
0000 0000 8184 8345
P214
P27
P31
P373
Eduardo Díaz-Rubio García
P496
0000-0003-2792-5348
P569
1946-01-01T00:00:00Z
1946-10-02T00:00:00Z